Mount Sinai joins effort to develop COVID-19 hyperimmune globulin product candidate

The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune globulin product, it was announced yesterday. The COVID-HIG is prepared using convalescent plasma from COVID-19 patients to potentially prevent and treat the disease in the absence of a vaccine. The collaboration, which leverages $34.6 million in funding from the Department of Defense, includes a post-exposure prophylaxis study on health care providers at high risk of COVID-19 infection and other high-risk populations.